National Psoriasis Foundation backs bill to lower treatment costs
In response to the rising cost of treating psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) has teamed with 22 other patient advocacy and medical organizations to help ensure treatments for lifelong, chronic diseases remain accessible. The Coalition for Accessible Treatments is working with concerned members of Congress to build support for the bipartisan Patients' Access to Treatments Act (PATA) (H.R. 460), introduced by Rep. David McKinley (R-W.V.) and Rep. Lois Capps (D-Calif.).
How the bill would work
PATA urges Congress to address the increasing out-of-pocket costs for prescription drugs. If passed, this bill will:
- Limit your co-payments and out-of-pocket expenses on your biologics and other specialty medications.
- Eliminate financial barriers to ensure you have access to the medication your doctor prescribes.
If your member of Congress is interested in supporting this legislation please encourage them to contact Rep. David McKinley's office at firstname.lastname@example.org or 202.225.4172.
Cost a burden for patients
A recent study led by Dr. April Armstrong of the University of California, Davis that analyzed NPF data to determine the out-of-pocket costs facing people with psoriatic diseases, found that although roughly 91 percent of psoriasis and psoriatic arthritis patients were covered by insurance, the majority spent greater than $2,500 per year in out-of-pocket costs for their disease.